{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:37:12Z","timestamp":1762004232461},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2010,4,26]],"date-time":"2010-04-26T00:00:00Z","timestamp":1272240000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1007\/s00066-010-2091-8","type":"journal-article","created":{"date-parts":[[2010,4,30]],"date-time":"2010-04-30T05:13:24Z","timestamp":1272604404000},"page":"247-254","source":"Crossref","is-referenced-by-count":12,"title":["Advanced-Stage III\/IV Follicular Lymphoma"],"prefix":"10.1007","volume":"186","author":[{"given":"Frank","family":"Heinzelmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hellmut","family":"Ottinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Engelhard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Soekler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Bamberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Weinmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,4,26]]},"reference":[{"key":"2091_CR1","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1200\/JCO.2000.18.3.527","volume":"18","author":"J. Apostolidis","year":"2000","unstructured":"Apostolidis J, Gupta RK, Grenzelias D, et al. High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up. J Clin Oncol 2000;18:527\u2013536.","journal-title":"J Clin Oncol"},{"key":"2091_CR2","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","volume":"362","author":"K.M. Ardeshna","year":"2003","unstructured":"Ardeshna KM, Smith P, Norton A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 2003;362:516\u2013522.","journal-title":"Lancet"},{"key":"2091_CR3","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1034\/j.1600-0609.2002.01542.x","volume":"68","author":"A. Aviles","year":"2002","unstructured":"Aviles A, Delgado S, Fernandez R, et al. Combined therapy in advanced stages (III and IV) of follicular lymphoma increases the possibility of cure: results of a large controlled clinical trial. Eur J Haematol 2002;68:144\u2013149.","journal-title":"Eur J Haematol"},{"key":"2091_CR4","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1182\/blood.V86.8.3257.3257","volume":"86","author":"Y. Bastion","year":"1995","unstructured":"Bastion Y, Brice P, Haioun C, et al. Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. Blood 1995;86:3257\u2013362.","journal-title":"Blood"},{"key":"2091_CR5","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/sj.bmt.1704784","volume":"35","author":"D.W. Beelen","year":"2005","unstructured":"Beelen DW, Trenschel R, Casper J, et al. Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications. Bone Marrow Transplant 2005;35:233\u2013241.","journal-title":"Bone Marrow Transplant"},{"key":"2091_CR6","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1200\/JCO.1997.15.2.445","volume":"15","author":"P.J. Bierman","year":"1997","unstructured":"Bierman PJ, Vose JM, Anderson JR, et al. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin\u2019s lymphoma. J Clin Oncol 1997;15:445\u2013450.","journal-title":"J Clin Oncol"},{"key":"2091_CR7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00066-007-1627-z","volume":"183","author":"M. Bischof","year":"2007","unstructured":"Bischof M, Karagiozidis M, Krempien R, et al. Radiotherapy for orbital lymphoma. Outcome and late effects. Strahlenther Onkol 2007;183:17\u201322.","journal-title":"Strahlenther Onkol"},{"key":"2091_CR8","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","volume":"15","author":"P. Brice","year":"1997","unstructured":"Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d\u2019Etude des Lymphomes Folliculaires. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. J Clin Oncol 1997;15:1110\u20131117.","journal-title":"J Clin Oncol"},{"key":"2091_CR9","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1023\/A:1008399623564","volume":"11","author":"P. Brice","year":"2000","unstructured":"Brice P, Simon D, Bouabdallah R, et al. High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol. Ann Oncol 2000;11:1585\u20131590.","journal-title":"Ann Oncol"},{"key":"2091_CR10","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/annonc\/mdh425","volume":"15","author":"W. Brugger","year":"2004","unstructured":"Brugger W, Hirsch J, Grunebach F, et al. Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study. Ann Oncol 2004;15:1691\u20131698.","journal-title":"Ann Oncol"},{"key":"2091_CR11","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1182\/blood-2002-11-3615","volume":"103","author":"J. Casper","year":"2004","unstructured":"Casper J, Knauf W, Kiefer T, et al. Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. Blood 2004;103:725\u2013731.","journal-title":"Blood"},{"key":"2091_CR12","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S1053-4296(05)80028-1","volume":"5","author":"J.M. Cosset","year":"1995","unstructured":"Cosset JM, Socie G, Girinsky T, et al. Radiobiological and clinical bases for total body irradiation in the leukemias and lymphomas. Semin Radiat Oncol 1995;5:301\u2013315.","journal-title":"Semin Radiat Oncol"},{"key":"2091_CR13","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1200\/JCO.1993.11.4.644","volume":"11","author":"B.W. Dana","year":"1993","unstructured":"Dana BW, Dahlberg S, Nathwani BN, et al. Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol 1993;11:644\u2013651.","journal-title":"J Clin Oncol"},{"key":"2091_CR14","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1182\/blood-2004-10-3920","volume":"105","author":"E. Deconinck","year":"2005","unstructured":"Deconinck E, Foussard C, Milpied N, et al. High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood 2005;105:3817\u20133823.","journal-title":"Blood"},{"key":"2091_CR15","doi-asserted-by":"crossref","unstructured":"DeMonaco NA, Wu M, Osborn J, et al. Phase II trial of abbreviated CHOP-rituximab followed by 90Y-ibritumomab tiuxetan (Zevalin) and rituximab in patients with previously-untreated follicular non-Hodgkin lymphoma (NHL). Blood 2005;106:abstract 2449.","DOI":"10.1182\/blood.V106.11.2449.2449"},{"key":"2091_CR16","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1182\/blood-2003-05-1406","volume":"103","author":"R.D. Faulkner","year":"2004","unstructured":"Faulkner RD, Craddock C, Byrne JL, et al. BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood 2004;103:428\u2013434.","journal-title":"Blood"},{"key":"2091_CR17","doi-asserted-by":"crossref","first-page":"8447","DOI":"10.1200\/JCO.2005.03.1674","volume":"23","author":"R.I. Fisher","year":"2005","unstructured":"Fisher RI, LeBlanc M, Press OW, et al. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005;23:8447\u20138452.","journal-title":"J Clin Oncol"},{"key":"2091_CR18","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/sj.bmt.1703573","volume":"29","author":"D.L. Forrest","year":"2002","unstructured":"Forrest DL, Thompson K, Nevill TJ, et al. Allogeneic hematopoietic stem cell transplantation for progressive follicular lymphoma. Bone Marrow Transplant 2002;29:973\u2013978.","journal-title":"Bone Marrow Transplant"},{"key":"2091_CR19","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","volume":"108","author":"R. Forstpointner","year":"2006","unstructured":"Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006;108:4003\u20134008.","journal-title":"Blood"},{"key":"2091_CR20","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1182\/blood.V94.10.3325.422k13_3325_3333","volume":"94","author":"A.S. Freedman","year":"1999","unstructured":"Freedman AS, Neuberg D, Mauch P, et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999;94:3325\u20133333.","journal-title":"Blood"},{"key":"2091_CR21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hon.2900120102","volume":"12","author":"G. Ganem","year":"1994","unstructured":"Ganem G, Lambin P, Socie G, et al. Potential role for low dose limited-field radiation therapy (2 \u00d7 2 grays) in advanced low-grade non-Hodgkin\u2019s lymphomas. Hematol Oncol 1 1994;12:1\u20138.","journal-title":"Hematol Oncol 1"},{"key":"2091_CR22","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/s00066-008-1840-4","volume":"184","author":"J. Gerstein","year":"2008","unstructured":"Gerstein J, Kofahl-Krause D, Fruhauf J, et al. Complete remission of a lymphoma-associated chylothorax by radiotherapy of the celiac trunk and thoracic duct. Strahlenther Onkol 2008;184:484\u2013487.","journal-title":"Strahlenther Onkol"},{"key":"2091_CR23","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s00066-009-2022-8","volume":"185","author":"J. Gerstein","year":"2009","unstructured":"Gerstein J, Meyer A, Sykora KW, et al. M. Long-term renal toxicity in children following fractionated total-body irradiation (TBI) before allogeneic stem cell transplantation (SCT). Strahlenther Onkol 2009;185:751\u2013755.","journal-title":"Strahlenther Onkol"},{"key":"2091_CR24","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","volume":"103","author":"M. Ghielmini","year":"2004","unstructured":"Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly \u00d7 4 schedule. Blood 2 2004;103:4416\u20134423.","journal-title":"Blood 2"},{"key":"2091_CR25","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0360-3016(01)01626-1","volume":"51","author":"T. Girinsky","year":"2001","unstructured":"Girinsky T, Guillot-Vals D, Koscielny S, et al. A high and sustained response rate in refractory or relapsing low-grade lymphoma masses after low-dose radiation: analysis of predictive parameters of response to treatment. Int J Radiat Oncol Biol Phys 2001;51:148\u2013155.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2091_CR26","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3816\/CLM.2004.n.015","volume":"5","author":"L.I. Gordon","year":"2004","unstructured":"Gordon LI, Witzig T, Molina A, et al. Yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin Lymphoma 2004;5:98\u2013101.","journal-title":"Clin Lymphoma"},{"key":"2091_CR27","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.ijrobp.2003.11.017","volume":"59","author":"R.L. Haas","year":"2004","unstructured":"Haas RL, de Jong D, Valdes Olmos RA, et al. In vivo imaging of radiation-induced apoptosis in follicular lymphoma patients. Int J Radiat Oncol Biol Phys 2004;59:782\u2013787.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2091_CR28","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1007\/s00277-003-0655-8","volume":"82","author":"R.L. Haas","year":"2003","unstructured":"Haas RL, Girinsky T. HOVON 47\/EORTC 20013: chlorambucil vs 2\u00d72 Gy involved field radiotherapy in stage III\/IV previously untreated follicular lymphoma patients. Ann Hematol 2 2003;82:458\u2013462.","journal-title":"Ann Hematol 2"},{"key":"2091_CR29","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.2003.09.542","volume":"21","author":"R.L. Haas","year":"2003","unstructured":"Haas RL, Poortmans P, de Jong D, et al. High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. J Clin Oncol 2003;21:2474\u20132480.","journal-title":"J Clin Oncol"},{"key":"2091_CR30","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1053\/sonc.2003.50023","volume":"30","author":"J.D. Hainsworth","year":"2003","unstructured":"Hainsworth JD. First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin\u2019s lymphoma. Semin Oncol 2003;30:9\u201315.","journal-title":"Semin Oncol"},{"key":"2091_CR31","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s00066-006-1468-1","volume":"182","author":"F. Heinzelmann","year":"2006","unstructured":"Heinzelmann F, Ottinger H, Muller CH, et al. Total-body irradiation \u2014 role and indications: results from the German Registry for Stem Cell Transplantation (DRST). Strahlenther Onkol 2006;182:222\u2013230.","journal-title":"Strahlenther Onkol"},{"key":"2091_CR32","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","volume":"25","author":"M. Herold","year":"2007","unstructured":"Herold M, Haas A, Srock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007;25:1986\u20131992.","journal-title":"J Clin Oncol"},{"key":"2091_CR33","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"W. Hiddemann","year":"2005","unstructured":"Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725\u20133732.","journal-title":"Blood"},{"key":"2091_CR34","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1023\/A:1008385202953","volume":"11","author":"S.J. Horning","year":"2000","unstructured":"Horning SJ. Follicular lymphoma: have we made any progress? Ann Oncol 2000;11:23\u201327.","journal-title":"Ann Oncol"},{"key":"2091_CR35","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/annonc\/mdg200","volume":"14","author":"C. Hosing","year":"2003","unstructured":"Hosing C, Saliba RM, McLaughlin P, et al. Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin\u2019s lymphoma. Ann Oncol 2003;14:737\u2013744.","journal-title":"Ann Oncol"},{"key":"2091_CR36","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/S0360-3016(02)03050-X","volume":"54","author":"J. Johannsson","year":"2002","unstructured":"Johannsson J, Specht L, Mejer J, et al. Phase II study of palliative low-dose local radiotherapy in disseminated indolent non-Hodgkin\u2019s lymphoma and chronic lymphocytic leukemia. Int J Radiat Oncol Biol Phys 2002;54:1466\u20131470.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2091_CR37","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1200\/JCO.1995.13.1.140","volume":"13","author":"P.W. Johnson","year":"1995","unstructured":"Johnson PW, Rohatiner AZ, Whelan JS, et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 1995;13:140\u2013147.","journal-title":"J Clin Oncol"},{"key":"2091_CR38","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJMoa041511","volume":"352","author":"M.S. Kaminski","year":"2005","unstructured":"Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005;352:441\u2013449.","journal-title":"N Engl J Med"},{"key":"2091_CR39","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1182\/blood.V98.13.3595","volume":"98","author":"I.F. Khouri","year":"2001","unstructured":"Khouri IF, Saliba RM, Giralt SA, et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 2001;98:3595\u20133599.","journal-title":"Blood"},{"key":"2091_CR40","doi-asserted-by":"crossref","unstructured":"Khouri IF, Saliba RM, Hosing CM, et al. Autologous stem cell (AUTO) vs non-myeloablative allogeneic transplantation (NMT) after high-dose rituximab (HD-R)-containing conditioning regimens for relapsed chemosensitve follicular lymphoma (FL). Blood 2005;106:abstract 48.","DOI":"10.1182\/blood.V106.11.48.48"},{"key":"2091_CR41","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/sj.bmt.1703790","volume":"31","author":"T.L. Kiss","year":"2003","unstructured":"Kiss TL, Panzarella T, Messner HA, et al. Busulfan and cyclophosphamide as a preparative regimen for allogeneic blood and marrow transplantation in patients with non-Hodgkin\u2019s lymphoma. Bone Marrow Transplant 2003;31:73\u201378.","journal-title":"Bone Marrow Transplant"},{"key":"2091_CR42","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/sj.bmt.1705027","volume":"36","author":"E. Kusumi","year":"2005","unstructured":"Kusumi E, Kami M, Kanda Y, et al. Reduced-intensity hematopoietic stem-cell transplantation for malignant lymphoma: a retrospective survey of 112 adult patients in Japan. Bone Marrow Transplant 2005;36:205\u2013213.","journal-title":"Bone Marrow Transplant"},{"key":"2091_CR43","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2004-03-0982","volume":"104","author":"G. Lenz","year":"2004","unstructured":"Lenz G, Dreyling M, Schiegnitz E, et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 2004;104:2667\u20132674.","journal-title":"Blood"},{"key":"2091_CR44","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1182\/blood.V91.1.331","volume":"91","author":"B.M. Leonard","year":"1998","unstructured":"Leonard BM, Hetu F, Busque L, et al. Lymphoma cell burden in progenitor cell grafts measured by competitive polymerase chain reaction: less than one log difference between bone marrow and peripheral blood sources. Blood 1998;91:331\u2013339.","journal-title":"Blood"},{"key":"2091_CR45","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1200\/JCO.2005.14.803","volume":"23","author":"J.P. Leonard","year":"2005","unstructured":"Leonard JP, Coleman M, Kostakoglu L, et al. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I-131 tositumomab for untreated follicular lymphoma. J Clin Oncol 2005;23:5696\u20135704.","journal-title":"J Clin Oncol"},{"key":"2091_CR46","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/bmj.1.6112.533","volume":"1","author":"T.A. Lister","year":"1978","unstructured":"Lister TA, Cullen MH, Beard ME, et al. Comparison of combined and single-agent chemotherapy in non-Hodgkin\u2019s lymphoma of favourable histological type. Br Med J 1978;1:533\u2013537.","journal-title":"Br Med J"},{"key":"2091_CR47","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1200\/JCO.2005.03.3696","volume":"24","author":"Q. Liu","year":"2006","unstructured":"Liu Q, Fayad L, Cabanillas F, et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol 2006;24:1582\u20131589.","journal-title":"J Clin Oncol"},{"key":"2091_CR48","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1182\/asheducation-2007.1.226","volume":"2007","author":"D.G. Maloney","year":"2007","unstructured":"Maloney DG. Follicular NHL: from antibodies and vaccines to graft-versus-lymphoma effects. Hematology Am Soc Hematol Educ Program 2007;2007:226\u2013232.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2091_CR49","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1046\/j.1365-2141.1998.00539.x","volume":"100","author":"C.M. Mandigers","year":"1998","unstructured":"Mandigers CM, Raemaekers JM, Schattenberg AV, et al. Allogeneic bone marrow transplantation with T-cell-depleted marrow grafts for patients with poor-risk relapsed low-grade non-Hodgkin\u2019s lymphoma. Br J Haematol 1998;100:198\u2013206.","journal-title":"Br J Haematol"},{"key":"2091_CR50","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","volume":"105","author":"R. Marcus","year":"2005","unstructured":"Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417\u20131423.","journal-title":"Blood"},{"key":"2091_CR51","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","volume":"26","author":"R. Marcus","year":"2008","unstructured":"Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008;26:4579\u20134586.","journal-title":"J Clin Oncol"},{"key":"2091_CR52","doi-asserted-by":"crossref","unstructured":"Maris MB, Sandmaier BM, Storer B, et al. Allogeneic hematopoietic cell transplantation (HCT) after nonmyeloablative conditioning for relapsed or refractory follicular lymphoma. Blood 2005;106:abstract 1130.","DOI":"10.1182\/blood.V106.11.1130.1130"},{"key":"2091_CR53","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/blood-2004-03-1105","volume":"104","author":"E. Morris","year":"2004","unstructured":"Morris E, Thomson K, Craddock C, et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 2004;104:3865\u20133871.","journal-title":"Blood"},{"key":"2091_CR54","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1200\/JCO.2008.17.2015","volume":"26","author":"F. Morschhauser","year":"2008","unstructured":"Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008;26:5156\u20135164.","journal-title":"J Clin Oncol"},{"key":"2091_CR55","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1440-1673.2006.01566.x","volume":"50","author":"M. Ng","year":"2006","unstructured":"Ng M, Wirth A, Ryan G, et al. Value of low-dose 2 \u00d7 2 Gy palliative radiotherapy in advanced low-grade non-Hodgkin\u2019s lymphoma. Australas Radiol 2006;50:222\u2013227.","journal-title":"Australas Radiol"},{"key":"2091_CR56","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/cncr.22093","volume":"107","author":"C. Nickenig","year":"2006","unstructured":"Nickenig C, Dreyling M, Hoster E, et al. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. Cancer 2006;107:1014\u20131022.","journal-title":"Cancer"},{"key":"2091_CR57","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1007\/s00066-003-1062-8","volume":"179","author":"O.J. Ott","year":"2003","unstructured":"Ott OJ, Rodel C, Gramatzki M, et al. Radiotherapy for stage I\u2013III nodal low-grade non-Hodgkin\u2019s lymphoma. Strahlenther Onkol 2003;179:694\u2013701.","journal-title":"Strahlenther Onkol"},{"key":"2091_CR58","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/sj.bmt.1703891","volume":"31","author":"A.J. Peniket","year":"2003","unstructured":"Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 2003;31:667\u2013678.","journal-title":"Bone Marrow Transplant"},{"key":"2091_CR59","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00066-007-1565-9","volume":"183","author":"A. Perez","year":"2007","unstructured":"Perez A, Grabenbauer GG, Sprung CN, et al. Potential for the G2\/M arrest assay to predict patient susceptibility to severe reactions following radiotherapy. Strahlenther Onkol 2007;183:99\u2013106.","journal-title":"Strahlenther Onkol"},{"key":"2091_CR60","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00066-009-1007-y","volume":"185","author":"P. Pommier","year":"2009","unstructured":"Pommier P, Sunyach MP, Pasteuris C, et al. Second cancer after total-body irradiation (TBI) in childhood. Strahlenther Onkol 2009;185:13\u201316.","journal-title":"Strahlenther Onkol"},{"key":"2091_CR61","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1200\/JCO.2006.05.8198","volume":"24","author":"O.W. Press","year":"2006","unstructured":"Press OW, Unger JM, Braziel RM, et al. Phase II trial of CHOP chemotherapy followed by tositumomab\/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin\u2019s lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 2006;24:4143\u20134149.","journal-title":"J Clin Oncol"},{"key":"2091_CR62","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1182\/blood.V84.4.1050.1050","volume":"84","author":"V. Ratanatharathorn","year":"1994","unstructured":"Ratanatharathorn V, Uberti J, Karanes C, et al. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin\u2019s lymphoma. Blood 1994;84:1050\u20131055.","journal-title":"Blood"},{"key":"2091_CR63","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00066-009-1008-x","volume":"185","author":"U. Ricardi","year":"2009","unstructured":"Ricardi U, Filippi AR, Biasin E, et al. Late toxicity in children undergoing hematopoietic stem cell transplantation with TBI-containing conditioning regimens for hematological malignancies. Strahlenther Onkol 2009;185:17\u201320.","journal-title":"Strahlenther Onkol"},{"key":"2091_CR64","doi-asserted-by":"crossref","first-page":"4310","DOI":"10.1182\/blood-2001-11-0107","volume":"100","author":"S.P. Robinson","year":"2002","unstructured":"Robinson SP, Goldstone AH, Mackinnon S, et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002;100:4310\u20134316.","journal-title":"Blood"},{"key":"2091_CR65","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1200\/JCO.2005.06.146","volume":"23","author":"A.Z. Rohatiner","year":"2005","unstructured":"Rohatiner AZ, Gregory WM, Peterson B, et al. Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 2005;23:2215\u20132223.","journal-title":"J Clin Oncol"},{"key":"2091_CR66","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1200\/JCO.1994.12.6.1177","volume":"12","author":"A.Z. Rohatiner","year":"1994","unstructured":"Rohatiner AZ, Johnson PW, Price CG, et al. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol 1994;12:1177\u20131184.","journal-title":"J Clin Oncol"},{"key":"2091_CR67","doi-asserted-by":"crossref","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood 2009;114:ASH Annual Meeting Abstracts:abstract 405.","DOI":"10.1182\/blood.V114.22.405.405"},{"key":"2091_CR68","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00066-005-1330-x","volume":"181","author":"K. Sakata","year":"2005","unstructured":"Sakata K, Satoh M, Someya M, et al. Analysis of local control in patients with non-Hodgkin\u2019s lymphoma according to the WHO classification. Strahlenther Onkol 2005;181:385\u2013391.","journal-title":"Strahlenther Onkol"},{"key":"2091_CR69","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1182\/blood-2008-04-153189","volume":"112","author":"G. Salles","year":"2008","unstructured":"Salles G, Mounier N, de Guibert S, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 2008;112:4824\u20134831.","journal-title":"Blood"},{"key":"2091_CR70","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0167-8140(96)01854-3","volume":"42","author":"E.J. Sawyer","year":"1997","unstructured":"Sawyer EJ, Timothy AR. Low dose palliative radiotherapy in low grade non-Hodgkin\u2019s lymphoma. Radiother Oncol 1997;42:49\u201351.","journal-title":"Radiother Oncol"},{"key":"2091_CR71","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00066-007-1656-7","volume":"183","author":"R.A. Schneider","year":"2007","unstructured":"Schneider RA, Schultze J, Jensen JM, et al. 20 years of experience in static intensity-modulated total-body irradiation and lung toxicity. Results in 257 consecutive patients. Strahlenther Onkol 2007;183:545\u2013551.","journal-title":"Strahlenther Onkol"},{"key":"2091_CR72","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2003.10.023","volume":"21","author":"H.C. Schouten","year":"2003","unstructured":"Schouten HC, Qian W, Kvaloy S, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin\u2019s lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003;21:3918\u20133927.","journal-title":"J Clin Oncol"},{"key":"2091_CR73","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1200\/JCO.2007.15.5358","volume":"26","author":"C. Sebban","year":"2008","unstructured":"Sebban C, Brice P, Delarue R, et al. Impact of rituximab and\/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. J Clin Oncol 2008;26:3614\u20133620.","journal-title":"J Clin Oncol"},{"key":"2091_CR74","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1182\/blood-2006-03-013193","volume":"108","author":"C. Sebban","year":"2006","unstructured":"Sebban C, Mounier N, Brousse N, et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA). Blood 2006;108:2540\u20132544.","journal-title":"Blood"},{"key":"2091_CR75","doi-asserted-by":"crossref","unstructured":"Shipley DL, Greco FA, Spigel DR, et al. Rituximab with short duration chemotherapy followed by 90Y-ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: update of a Minnie Pearl Cancer Research Network phase II trial. Blood 2005;23:Suppl: Abstract 6577.","DOI":"10.1200\/jco.2005.23.16_suppl.6577"},{"key":"2091_CR76","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/sj.bmt.1704118","volume":"32","author":"T.E. Tanimoto","year":"2003","unstructured":"Tanimoto TE, Kusumi E, Hamaki T, et al. High complete response rate after allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimens in advanced malignant lymphoma. Bone Marrow Transplant 2003;32:131\u2013137.","journal-title":"Bone Marrow Transplant"},{"key":"2091_CR77","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2141.2004.05194.x","volume":"127","author":"C.L. Toze","year":"2004","unstructured":"Toze CL, Barnett MJ, Connors JM, et al. Long-term disease-free survival of patients with advanced follicular lymphoma after allogeneic bone marrow transplantation. Br J Haematol 2004;127:311\u2013321.","journal-title":"Br J Haematol"},{"key":"2091_CR78","doi-asserted-by":"crossref","unstructured":"van Besien K, Carreras J, Zhang M-J, et al. Reduced intensity vs myeloablative conditioning for HLA matched sibling transplantation in follicular lymphoma. Blood 2005;106:abstract 656.","DOI":"10.1182\/blood.V106.11.656.656"},{"key":"2091_CR79","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1182\/blood-2003-04-1205","volume":"102","author":"K. Besien van","year":"2003","unstructured":"van Besien K, Loberiza FR Jr, Bajorunaite R, et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003;102:3521\u20133529.","journal-title":"Blood"},{"key":"2091_CR80","first-page":"1832","volume":"92","author":"K. Besien van","year":"1998","unstructured":"van Besien K, Sobocinski KA, Rowlings PA, et al. Allogeneic bone marrow transplantation for low-grade lymphoma. Blood 1998;92:1832\u20131836.","journal-title":"Blood"},{"key":"2091_CR81","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/sj.bmt.1700781","volume":"19","author":"K.W. Besien van","year":"1997","unstructured":"van Besien KW, de Lima M, Giralt SA, et al. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplant 1997;19:977\u2013982.","journal-title":"Bone Marrow Transplant"},{"key":"2091_CR82","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1200\/JCO.1995.13.5.1096","volume":"13","author":"K.W. Besien van","year":"1995","unstructured":"van Besien KW, Khouri IF, Giralt SA, et al. Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management. J Clin Oncol 1995;13:1096\u20131102.","journal-title":"J Clin Oncol"},{"key":"2091_CR83","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","volume":"108","author":"M.H. Oers van","year":"2006","unstructured":"van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 Intergroup trial. Blood 2006;108:3295\u20133301.","journal-title":"Blood"},{"key":"2091_CR84","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3109\/10428199909083388","volume":"34","author":"L.F. Verdonck","year":"1999","unstructured":"Verdonck LF. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin\u2019s lymphoma: updated results of the Utrecht experience. Leuk Lymphoma 1999;34:129\u2013136.","journal-title":"Leuk Lymphoma"},{"key":"2091_CR85","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3324\/haematol.10924","volume":"92","author":"S. Vigouroux","year":"2007","unstructured":"Vigouroux S, Michallet M, Porcher R, et al. Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). Haematologica 2007;92:627\u2013634.","journal-title":"Haematologica"},{"key":"2091_CR86","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.1182\/blood.V99.12.4336","volume":"99","author":"G.A. Wiseman","year":"2002","unstructured":"Wiseman GA, Gordon LI, Multani PS, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002;99:4336\u20134342.","journal-title":"Blood"},{"key":"2091_CR87","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","volume":"20","author":"T.E. Witzig","year":"2002","unstructured":"Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin\u2019s lymphoma. J Clin Oncol 2002;20:3262\u20133269.","journal-title":"J Clin Oncol"},{"key":"2091_CR88","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","volume":"20","author":"T.E. Witzig","year":"2002","unstructured":"Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin\u2019s lymphoma. J Clin Oncol 2002;20:2453\u20132463.","journal-title":"J Clin Oncol"},{"key":"2091_CR89","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1002\/cncr.22617","volume":"109","author":"T.E. Witzig","year":"2007","unstructured":"Witzig TE, Molina A, Gordon LI, et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium-90-ibritumomab tiuxetan. Cancer 2007;109:1804\u20131810.","journal-title":"Cancer"},{"key":"2091_CR90","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1200\/JCO.2003.08.043","volume":"21","author":"T.E. Witzig","year":"2003","unstructured":"Witzig TE, White CA, Gordon, LI, et al. Safety of yttrium-90-ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin\u2019s lymphoma. J Clin Oncol 2003;21:1263\u20131270.","journal-title":"J Clin Oncol"},{"key":"2091_CR91","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/sj.bmt.1703625","volume":"30","author":"I. Yakoub-Agha","year":"2002","unstructured":"Yakoub-Agha I, Fawaz A, Folliot O, et al. Allogeneic bone marrow transplantation in patients with follicular lymphoma: a single center study. Bone Marrow Transplant 2002;30:229\u2013234.","journal-title":"Bone Marrow Transplant"},{"key":"2091_CR92","first-page":"11","volume":"25","author":"R.C. Young","year":"1988","unstructured":"Young RC, Longo DL, Glatstein E, et al. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Hematol 1988;25:11\u201316.","journal-title":"Semin Hematol"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-010-2091-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00066-010-2091-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-010-2091-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T05:29:24Z","timestamp":1591248564000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00066-010-2091-8"}},"subtitle":["Treatment Strategies for Individual Patients"],"short-title":[],"issued":{"date-parts":[[2010,4,26]]},"references-count":92,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["2091"],"URL":"https:\/\/doi.org\/10.1007\/s00066-010-2091-8","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,26]]}}}